CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 220 enrolled
Drug / intervention
Lonapegsomatropindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05171855
NCT05171855Phase 3Completed
CompareCT.gov

A Multicenter, Open-Label, Extension Trial to Investigate Long Term Efficacy and Safety of Lonapegsomatropin in Adults With Growth Hormone Deficiency

Ascendis Pharma Endocrinology Division A/S·interventional·Posted Dec 29, 2021·Updated Jan 9, 2026

In Brief

A Phase 3 clinical trial evaluating Lonapegsomatropin for Adult Growth Hormone Deficiency and 2 related conditions. Completed, enrolled 220 participants across 85 sites in 21 countries.

Detailed Summary

This was a phase 3 open-label multicenter extension study designed to evaluate the long-term safety and efficacy of Lonapegsomatropin administered once-weekly. The study participants were adults (males and females) with confirmed growth hormone deficiency (GHD) having completed the treatment period in study TCH-306 (foresiGHt; NCT04615273).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdult Growth Hormone Deficiency, Endocrine System Diseases, Hormone Deficiency
CountriesArmenia, Australia, Canada, France, Georgia, Germany, Greece, Israel, Italy, Japan, Malaysia, Poland, Romania, Serbia, Slovakia, South Korea, Spain, Turkey (Türkiye), Ukraine, United Kingdom, United States
Collaborators--

Timeline

Phase 3CompletedFinished
20222023202420252026
First PostedDec 29, 2021
Enrollment StartDec 16, 2021
Primary CompletionDec 23, 2024
TodayJul 2, 2026
Enrollment to primary: 3.0 yearsPosted 4.5 years ago

Interventions

Lonapegsomatropindrug

Study participants were individually dosed with subcutaneous injection of Lonapegsomatropin once-weekly for 52 weeks.